On Tuesday, company revealed that its subcutaneous formulation of Keytruda has aced a phase 3 trial, demonstrating ...

Merck & Co. Inc.'s reported positive results Tuesday for a new, easier-to-administer formulation of its blockbuster cancer drug Keytruda. Rahway, N.J.-based Merck (MRK) said a trial of the drug, given ...

The phase 3 MK-3475A-D77 trial tested subcutaneous and intravenous Keytruda given every six weeks in combination with ...

Eikon Therapeutics, Inc., a pioneering biotechnology company that leverages advanced engineering to enhance drug discovery ...

Merck Research Laboratories. “It is very encouraging to see positive Phase 3 results evaluating this fixed-dose combination of subcutaneous pembrolizumab, which was administered, on average, in ...

Founded with a mission to address the “last-mile” challenges in pain relief, Doloromics integrates artificial intelligence ...

In September 2024, UCB and Biogen reported successful results from their Phase III clinical trial of the PHOENYCS GO study, which tested dapirolizumab pegol as a treatment for moderate-to-severe ...

Investor confidence may be returning, with biopharma venture funding, deal value and exit activity all rising in 2024’s third ...

Global Metastatic Colorectal Cancer Market to Record Stellar Growth with Advancements in Treatments and Rise in Healthcare InfrastructuresRockville, MD, Nov. 20, 2024 (GLOBE NEWSWIRE) -- According to ...

When combined into sectors, my dad had a large overweight to Health Care and both Consumer sectors, combined accounting for ...

Cell Culture Market. The global cell culture market is poised for significant growth, with projections estimating a rise from ...